Short Interest in FocalTherics (NASDAQ:FOCL) Increases By 69.0%

FocalTherics (NASDAQ:FOCL) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 57,027 shares, a growth of 69.0% from the April 30th total of 33,750 shares. Currently, 0.2% of the shares of the company are short sold. Based on an average trading volume of 48,517 shares, the short-interest ratio is presently 1.2 days.

FocalTherics Price Performance

FocalTherics stock opened at $4.62 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. FocalTherics has a one year low of $1.21 and a one year high of $5.05.

FocalTherics (NASDAQ:FOCL) last released its earnings results on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). FocalTherics had a negative return on equity of 137.61% and a negative net margin of 41.47%.The company had revenue of $20.48 million for the quarter, compared to analyst estimates of $19.46 million. On average, equities analysts forecast that FocalTherics will post -0.82 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on FOCL. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of FocalTherics in a research note on Tuesday. Wall Street Zen cut FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, FocalTherics currently has a consensus rating of “Hold” and an average price target of $6.00.

Insider Activity

In other news, Director Joshua Levine acquired 10,000 shares of FocalTherics stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $4.22 per share, for a total transaction of $42,200.00. Following the completion of the acquisition, the director directly owned 35,000 shares in the company, valued at approximately $147,700. The trade was a 40.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On FocalTherics

Hedge funds have recently bought and sold shares of the company. Financial Planning Navigators CORP bought a new stake in shares of FocalTherics during the 4th quarter worth approximately $33,000. Leonteq Securities AG bought a new position in FocalTherics in the fourth quarter valued at approximately $313,000. Kovack Advisors Inc. bought a new position in FocalTherics in the fourth quarter valued at approximately $53,000. Rock Springs Capital Management LP raised its position in FocalTherics by 1.3% during the fourth quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the company’s stock valued at $4,233,000 after purchasing an additional 16,500 shares in the last quarter. Finally, Flax Pond Capital LLC acquired a new position in FocalTherics during the fourth quarter valued at approximately $2,623,000. 62.74% of the stock is owned by institutional investors.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.